[
  {
    "ts": null,
    "headline": "3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly",
    "summary": "Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year.  Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to be a dominant player in the weight loss and diabetes markets.  Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term.",
    "url": "https://finnhub.io/api/news?id=01bba6fb2e39c86c6c5303c70c340d3cd7ff350a779969f83a2d920a29f8e8ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752099360,
      "headline": "3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly",
      "id": 135839398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year.  Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to be a dominant player in the weight loss and diabetes markets.  Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term.",
      "url": "https://finnhub.io/api/news?id=01bba6fb2e39c86c6c5303c70c340d3cd7ff350a779969f83a2d920a29f8e8ed"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=defcd7e7490655ae8c9fd05d04883ec4dba7afd38a70b56392269ec9b934b77a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752097503,
      "headline": "Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 135841802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=defcd7e7490655ae8c9fd05d04883ec4dba7afd38a70b56392269ec9b934b77a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule",
    "summary": "Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related imaging abnormalities in Alzheimer's treatment. This development comes amid a 3% price increase for the company in the last quarter. Despite these gains, market activity remained relatively flat over this period, reflecting industry-wide trends. Liquidity, investor sentiment toward tech giants, and market influences such as revised U.S. trade policy and Nvidia's market...",
    "url": "https://finnhub.io/api/news?id=41ab4da7513a60aee07c802b952362083243db019e5f964b1df1b4af4bb1a17d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752082533,
      "headline": "Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule",
      "id": 135841804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related imaging abnormalities in Alzheimer's treatment. This development comes amid a 3% price increase for the company in the last quarter. Despite these gains, market activity remained relatively flat over this period, reflecting industry-wide trends. Liquidity, investor sentiment toward tech giants, and market influences such as revised U.S. trade policy and Nvidia's market...",
      "url": "https://finnhub.io/api/news?id=41ab4da7513a60aee07c802b952362083243db019e5f964b1df1b4af4bb1a17d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a1c6d282e5fbf64c671be6b81afc437661ca6cfd82374b96559b2a16dbc75b49",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752078660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 135854924,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a1c6d282e5fbf64c671be6b81afc437661ca6cfd82374b96559b2a16dbc75b49"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?",
    "summary": "NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.",
    "url": "https://finnhub.io/api/news?id=eb7a3324c98ee8e8e5436f5f101d805a510c9194fc419581f4279ec1906e510a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752076080,
      "headline": "Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?",
      "id": 135835677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.",
      "url": "https://finnhub.io/api/news?id=eb7a3324c98ee8e8e5436f5f101d805a510c9194fc419581f4279ec1906e510a"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street waves off Trump's 200% pharma tariff threat",
    "summary": "President Trump threatened as much as 200% tariffs on pharma Tuesday. By Wednesday morning, Wall Street had ignored the threat.",
    "url": "https://finnhub.io/api/news?id=f696d5cb21c2f80d43981b6002d0e6a0abf371941220b1f8f1f952da059a4a90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752075698,
      "headline": "Wall Street waves off Trump's 200% pharma tariff threat",
      "id": 135835678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump threatened as much as 200% tariffs on pharma Tuesday. By Wednesday morning, Wall Street had ignored the threat.",
      "url": "https://finnhub.io/api/news?id=f696d5cb21c2f80d43981b6002d0e6a0abf371941220b1f8f1f952da059a4a90"
    }
  },
  {
    "ts": null,
    "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
    "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
    "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067440,
      "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
      "id": 135835679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
      "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck",
    "summary": "VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.",
    "url": "https://finnhub.io/api/news?id=16a0ec4ea00adf94ea44aea98aaef434dd1c577df6835043c52dfcfc4f21af13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067140,
      "headline": "Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck",
      "id": 135835680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.",
      "url": "https://finnhub.io/api/news?id=16a0ec4ea00adf94ea44aea98aaef434dd1c577df6835043c52dfcfc4f21af13"
    }
  },
  {
    "ts": null,
    "headline": "Concentra Group Holdings (CON) Strengthens Board to Accelerate Growth",
    "summary": "Concentra Group Holdings Parent, Inc. (NYSE:CON) is one of the 15 successful spin-off companies. On June 26, the company confirmed the appointment of two new board members as it looks to unlock new growth opportunities and enhance shareholder value. The company confirmed the appointment of Vipin Gopal and Brigid Bonner to its board, effective July […]",
    "url": "https://finnhub.io/api/news?id=04da149b761d324af8c0b22a756057abe9a6eb1de3863d09368ffd5e8db14d2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752060876,
      "headline": "Concentra Group Holdings (CON) Strengthens Board to Accelerate Growth",
      "id": 135835030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Concentra Group Holdings Parent, Inc. (NYSE:CON) is one of the 15 successful spin-off companies. On June 26, the company confirmed the appointment of two new board members as it looks to unlock new growth opportunities and enhance shareholder value. The company confirmed the appointment of Vipin Gopal and Brigid Bonner to its board, effective July […]",
      "url": "https://finnhub.io/api/news?id=04da149b761d324af8c0b22a756057abe9a6eb1de3863d09368ffd5e8db14d2a"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?",
    "summary": "President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus market for drug imports. Here's a breakdown of which countries—and medicines—could be exposed.",
    "url": "https://finnhub.io/api/news?id=2b9b9ef493b1fddef093886a32bfd6c24900ca4ffac738467cb34bca5e5a6cc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752060580,
      "headline": "Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?",
      "id": 135835682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus market for drug imports. Here's a breakdown of which countries—and medicines—could be exposed.",
      "url": "https://finnhub.io/api/news?id=2b9b9ef493b1fddef093886a32bfd6c24900ca4ffac738467cb34bca5e5a6cc2"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Lilly's once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people in the mild dementia stage of AD, with confirmed amyloid pathology.1,2 In the TRAILBLAZER-ALZ 6 study, the mod",
    "url": "https://finnhub.io/api/news?id=a17e883585480be6f5092570abe8c85ac2a4575269855b2f4e365d03af7a917b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752057900,
      "headline": "FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease",
      "id": 135835684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Lilly's once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people in the mild dementia stage of AD, with confirmed amyloid pathology.1,2 In the TRAILBLAZER-ALZ 6 study, the mod",
      "url": "https://finnhub.io/api/news?id=a17e883585480be6f5092570abe8c85ac2a4575269855b2f4e365d03af7a917b"
    }
  },
  {
    "ts": null,
    "headline": "Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck",
    "summary": "The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacotherapies and personalized medicine are offering more effective solutions, while telemedicine and online support expand treatment accessibility. Despite challenges like high costs and stigma, especially in developing regions, the market shows potential for further growth. Key",
    "url": "https://finnhub.io/api/news?id=fed1316f34d0de070150e0b30c25f5bda1c835c19ceb3d892fcd790ae67540ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752056100,
      "headline": "Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck",
      "id": 135833426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacotherapies and personalized medicine are offering more effective solutions, while telemedicine and online support expand treatment accessibility. Despite challenges like high costs and stigma, especially in developing regions, the market shows potential for further growth. Key",
      "url": "https://finnhub.io/api/news?id=fed1316f34d0de070150e0b30c25f5bda1c835c19ceb3d892fcd790ae67540ec"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: new recommended dosage for Kisunla",
    "summary": "Eli Lilly has announced that the US FDA has approved a label update with a new recommended dosing regimen for Kisunla, its bimonthly treatment for adults with early symptomatic Alzheimer's disease.The...",
    "url": "https://finnhub.io/api/news?id=06fb9880bd86ed1a610273034e1f1468edc2bfcbd1c6b858072d7c9e7317e5c9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752049758,
      "headline": "Eli Lilly: new recommended dosage for Kisunla",
      "id": 135833242,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that the US FDA has approved a label update with a new recommended dosing regimen for Kisunla, its bimonthly treatment for adults with early symptomatic Alzheimer's disease.The...",
      "url": "https://finnhub.io/api/news?id=06fb9880bd86ed1a610273034e1f1468edc2bfcbd1c6b858072d7c9e7317e5c9"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "summary": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752049080,
      "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
      "id": 135833163,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease",
    "summary": "Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a label update with a new recommended titration dosing schedule for Kisunla , Lilly's once-monthly...",
    "url": "https://finnhub.io/api/news?id=4e0cd94b98b6f7c1010c9013fe4035c80d0f8756faa09ba25730b63bbbf4d7bd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752046521,
      "headline": "Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease",
      "id": 135832848,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a label update with a new recommended titration dosing schedule for Kisunla , Lilly's once-monthly...",
      "url": "https://finnhub.io/api/news?id=4e0cd94b98b6f7c1010c9013fe4035c80d0f8756faa09ba25730b63bbbf4d7bd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly FDA approves updated label for Kisunla",
    "summary": "Eli Lilly and Co: Eli Lilly: FDA approval updated label for Kisunla with new dosing in early symptomatic Alzheimer's disease Eli Lilly: newly recommended dosing schedule significant lowered...",
    "url": "https://finnhub.io/api/news?id=766578c38a5edfd9b49dc50a89665b2955187c7f0ec507689352a0bdcf022b06",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752043933,
      "headline": "Eli Lilly FDA approves updated label for Kisunla",
      "id": 135832587,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: Eli Lilly: FDA approval updated label for Kisunla with new dosing in early symptomatic Alzheimer's disease Eli Lilly: newly recommended dosing schedule significant lowered...",
      "url": "https://finnhub.io/api/news?id=766578c38a5edfd9b49dc50a89665b2955187c7f0ec507689352a0bdcf022b06"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Announced Results for its Once-Weekly Insulin",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and Company (NYSE:LLY) announced new results for its once-weekly insulin, Efsitora alfa. The drug is being tested for adults with type 2 diabetes. The company released results for QWINT-1, QWINT-3, and […]",
    "url": "https://finnhub.io/api/news?id=4ca6c08377988c22cc72d3ed7ae711b5d1fa77634eed2a29c18001ae509cef49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752037396,
      "headline": "Eli Lilly (LLY) Announced Results for its Once-Weekly Insulin",
      "id": 135829717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and Company (NYSE:LLY) announced new results for its once-weekly insulin, Efsitora alfa. The drug is being tested for adults with type 2 diabetes. The company released results for QWINT-1, QWINT-3, and […]",
      "url": "https://finnhub.io/api/news?id=4ca6c08377988c22cc72d3ed7ae711b5d1fa77634eed2a29c18001ae509cef49"
    }
  }
]